| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/31/2011 | WO2010139469A3 Antibodies against human ccn1 and uses thereof |
| 03/31/2011 | WO2010135580A3 Fermented wheat germ proteins (fwgp) for the treatment of cancer |
| 03/31/2011 | WO2010135429A3 Compositions for modulating a kinase cascade and mehtods of use thereof |
| 03/31/2011 | WO2010132882A3 Sublingual dexmedetomidine compositions and methods of use thereof |
| 03/31/2011 | WO2010132879A3 Multicomponent degradable cationic polymers |
| 03/31/2011 | WO2010132507A3 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) |
| 03/31/2011 | WO2010128807A3 Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases |
| 03/31/2011 | WO2010121177A3 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| 03/31/2011 | WO2010115119A3 Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents |
| 03/31/2011 | WO2010114919A3 Metnase and intnase inhibitors and their use in treating cancer |
| 03/31/2011 | WO2010114312A3 Human monoclonal antibody that specifically binds to vcam-1 and a composition for treating an inflammatory disease or a cancer comprising the same |
| 03/31/2011 | WO2010104598A3 Kinase protein binding inhibitors |
| 03/31/2011 | WO2010093420A3 Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof |
| 03/31/2011 | WO2010085377A3 Hydroxamic acid derivatives |
| 03/31/2011 | WO2010083501A3 Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold |
| 03/31/2011 | WO2010052680A3 Composition for treatment of cancer |
| 03/31/2011 | WO2009129246A3 Compositions and methods for preparing and using same |
| 03/31/2011 | US20110077581 Targeted cellular delivery of nanoparticles |
| 03/31/2011 | US20110077572 Medical Equipment and Products using Chlorine, Hydrogen Peroxide, and Anti-Viral, Anti-Bacterial, Anti-Fungal, Agents, usage Method Improvements Dread Disease Cures, Remissions, and Anti-Infective Treatment Measures, Disease Treatment and Prevention System |
| 03/31/2011 | US20110077402 Administration of dipeptidyl peptidase inhibitors |
| 03/31/2011 | US20110077306 Stat3 inhibiting compositions and methods |
| 03/31/2011 | US20110077305 5-lipoxygenase inhibitors |
| 03/31/2011 | US20110077298 Retinoid Derivative and Pharmaceutical Composition and Use Thereof |
| 03/31/2011 | US20110077297 Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
| 03/31/2011 | US20110077295 Andrographolide derivatives and use thereof in manufacture of medicaments |
| 03/31/2011 | US20110077291 Preparations of Taxanes for Intravenous Administration and the Preparation Method Thereof |
| 03/31/2011 | US20110077290 Heterocyclic compounds and thrombopoietin receptor activators |
| 03/31/2011 | US20110077288 Pharmaceutical Compositions for Treatment of MicroRNA Related Diseases |
| 03/31/2011 | US20110077287 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions |
| 03/31/2011 | US20110077285 Rna antagonist compounds for the modulation of pik3ca expression |
| 03/31/2011 | US20110077268 Kinase inhibitors and methods of use |
| 03/31/2011 | US20110077265 Inhibitors of iap |
| 03/31/2011 | US20110077263 Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
| 03/31/2011 | US20110077256 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 03/31/2011 | US20110077254 Compounds |
| 03/31/2011 | US20110077252 Pyridyl derivatives, their preparation and use |
| 03/31/2011 | US20110077249 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives |
| 03/31/2011 | US20110077247 Class of histone deacetylase inhibitors |
| 03/31/2011 | US20110077237 Kinase inhibitors |
| 03/31/2011 | US20110077236 New carboxylic acid amides, the preparation thereof and their use as medicaments |
| 03/31/2011 | US20110077233 C-Met Modulators and Method of Use |
| 03/31/2011 | US20110077230 Copper organocomplexes, use thereof as antitumor means and for protecting healthy tissue from ionizing radiation |
| 03/31/2011 | US20110077221 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| 03/31/2011 | US20110077217 Selectively depolymerized galactomannan polysaccharide |
| 03/31/2011 | US20110077215 DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL) |
| 03/31/2011 | US20110077210 Hdac regulation assays, compounds and therapeutic compositions |
| 03/31/2011 | US20110077208 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 03/31/2011 | US20110077206 Use of hnf4alpha for treatment of human malignant solid tumors through induction-differentiation therapy |
| 03/31/2011 | US20110077205 Production and Use of Antitumoral Cyclodepsipeptides |
| 03/31/2011 | US20110077201 High affinity vegf-receptor antagonists |
| 03/31/2011 | US20110077198 Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| 03/31/2011 | US20110077194 Method for Treating or Preventing a Functional Vitamin B12 Deficiency in an Individual and to Medical Compositions for Use in Said Method |
| 03/31/2011 | US20110077193 Artemisinin Derivatives with Natural Amino Acids, Peptides, and Amino Sugars for the Treatment of Infection and Topical Condition in Mammals |
| 03/31/2011 | US20110077190 Selective Caspase Inhibitors and Uses Thereof |
| 03/31/2011 | US20110076766 Cytostatic Drug Composition |
| 03/31/2011 | US20110076763 Neoplasm specific antibodies and uses thereof |
| 03/31/2011 | US20110076344 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| 03/31/2011 | US20110076343 Multiple Myeloma Treatments |
| 03/31/2011 | US20110076342 Cancer peptide therapeutics |
| 03/31/2011 | US20110076335 Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| 03/31/2011 | US20110076319 Bioresorbable metal stent with controlled resorption |
| 03/31/2011 | US20110076317 Rapid establishment and/or termination of substantial steady-state drug delivery |
| 03/31/2011 | US20110076315 Grafts and Stents Having Inorganic Bio-Compatible Calcium Salt |
| 03/31/2011 | US20110076314 Hydrophobic polysaccharides with silyl ether linkages having enhanced degradation and medical articles made therefrom |
| 03/31/2011 | US20110076308 Micelle encapsulation of therapeutic agents |
| 03/31/2011 | US20110076296 TLR3 Agonist Compositions |
| 03/31/2011 | US20110076295 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 03/31/2011 | US20110076293 Triptolide derivatives for modulation of apoptosis and immunosuppression |
| 03/31/2011 | US20110076292 Benzoxazepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | US20110076291 Benzoxepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | US20110076290 Dendritic cell vaccines for asparaginyl-beta-hydroxylase expressing tumors |
| 03/31/2011 | US20110076287 Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| 03/31/2011 | US20110076286 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| 03/31/2011 | US20110076283 Method for predicting and diagnosing brain tumor |
| 03/31/2011 | US20110076282 Methods of killing cells and use of same in prevention and treatment of cancer |
| 03/31/2011 | US20110076280 Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| 03/31/2011 | US20110076279 Fully human anti-vegf antibodies and methods of using |
| 03/31/2011 | US20110076274 Materials and methods relating to a g-protein coupled receptor |
| 03/31/2011 | US20110076273 Highly Concentrated Pharmaceutical Formulations |
| 03/31/2011 | US20110076272 Therapeutic methods and compositions |
| 03/31/2011 | US20110076271 Diagnostic methods and compositions for treatment of cancer |
| 03/31/2011 | US20110076269 Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid |
| 03/31/2011 | US20110076267 Humanized antibody compositions and methods for binding lysophosphatidic acid |
| 03/31/2011 | US20110076266 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals |
| 03/31/2011 | US20110076264 Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| 03/31/2011 | US20110076254 Porous scaffolds for stem cell renewal |
| 03/31/2011 | US20110076249 Immunotherapy for immune suppressed patients |
| 03/31/2011 | US20110076238 Compounds for the treatment of proliferative processes |
| 03/31/2011 | US20110076234 Peptides comprising an isodgr motif |
| 03/31/2011 | US20110076233 Delivery System for Cytotoxic Drugs by Bispecific Antibody Pretargeting |
| 03/31/2011 | US20110076232 Specific binding proteins and uses thereof |
| 03/31/2011 | CA2812683A1 Lysine specific demethylase-1 inhibitors and their use |
| 03/31/2011 | CA2775874A1 Combination |
| 03/31/2011 | CA2775601A1 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| 03/31/2011 | CA2775475A1 Pyridinylimidazolone derivatives for inhibition of pi3 kinases |
| 03/31/2011 | CA2775400A1 New use of pdgfrbeta inhibitors |
| 03/31/2011 | CA2775350A1 Dr5 ligand drug conjugates |
| 03/31/2011 | CA2775296A1 Polymorphs of sorafenib acid addition salts |
| 03/31/2011 | CA2775204A1 Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors |
| 03/31/2011 | CA2775125A1 Combination |